Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Thom Brian David

2. Date of Event Requiring Statement (MM/DD/YYYY) 12/1/2020

3. Issuer Name and Ticker or Trading Symbol

United Health Products, Inc. [UEEC]

(Last) (First) (Middle)

10624 S EASTERN AVE., STE A209

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
CEO /

(Street)

HENDERSON, NV 89052

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock ⁽¹⁾	125000	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Convertible Notes ⁽²⁾	12/1/2020	3/31/2021	Common Stock	180000	$0.50	D
Convertible Notes ⁽³⁾	12/1/2020	3/31/2021	Common Stock	800000	$0.50	D
Restricted Stock Unit Awards	⁽⁴⁾	⁽⁴⁾	Common Stock	11500000	⁽⁴⁾	D

Explanation of Responses:
(1)	Excludes restricted stock unit awards totaling 11.5 million shares.
(2)	Represents services rendered totaling $90,000.
(3)	Represents cash loans.
(4)	The restricted stock unit awards vest upon performance and do not contain a conversion or exercise price. 5% of the RSU's vest upon FDA approval of the company's class III PMA, an additional 10% of the RSU's will vest upon the execution of each commercial distribution agreement for the marketing of its products up to a maximum of three such agreements and the balance will vest upon the company achieving $30 million in gross cumulative sales or a covered transaction as defined in the agreement.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Thom Brian David 10624 S EASTERN AVE. STE A209 HENDERSON, NV 89052			CEO